Regeneron isnt just buying a gold ticket to the GLP-1 show, as it also intends to use Hansohs GLP-1/GIP to study combinations with its proprietary drugs and candidates for addressing muscle loss and other obesity comorbidities like CVD and T2D
Journal of Neuroscience Research
Some practitioners add other peptides to address semaglutide limitations
A patient has to be enrolled in a participating Medicare Part D plan, and their provider must submit a prior authorization request establishing medical necessity
I think some of us have a conscious or unconscious bias that drugs are only to treat diseases, but I see no reason why this is obvious or true
These include changes to the central nervous system, irritability, fatigue, behavioral changes, tremors, headaches, problems hearing, skin damage and cognitive loss